Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Natural killer cells in the brain tumor microenvironment: Defining a new era in neuro-oncology.

Fares J, Fares MY, Fares Y.

Surg Neurol Int. 2019 Mar 26;10:43. doi: 10.25259/SNI-97-2019. eCollection 2019. No abstract available.

2.

The role of tumor board conferences in neuro-oncology: a nationwide provider survey.

Snyder J, Schultz L, Walbert T.

J Neurooncol. 2017 May;133(1):1-7. doi: 10.1007/s11060-017-2416-x. Epub 2017 Apr 18.

PMID:
28421461
3.

Ethical considerations of neuro-oncology trial design in the era of precision medicine.

Gupta S, Smith TR, Broekman ML.

J Neurooncol. 2017 Aug;134(1):1-7. doi: 10.1007/s11060-017-2502-0. Epub 2017 May 29. Review.

4.

Brain tumor biobanking in the precision medicine era: building a high-quality resource for translational research in neuro-oncology.

Ostrom QT, Devine K, Fulop J, Wolinsky Y, Liao P, Stetson L, Couce M, Sloan AE, Barnholtz-Sloan JS.

Neurooncol Pract. 2017 Dec;4(4):220-228. doi: 10.1093/nop/npw029. Epub 2016 Dec 30. Review. Erratum in: Neurooncol Pract. 2017 Jun;4(2):136.

5.

3D models in the new era of immune oncology: focus on T cells, CAF and ECM.

Di Modugno F, Colosi C, Trono P, Antonacci G, Ruocco G, Nisticò P.

J Exp Clin Cancer Res. 2019 Mar 22;38(1):117. doi: 10.1186/s13046-019-1086-2. Review.

6.

Society for Neuro-Oncology 2014 annual meeting updates on central nervous system metastases.

Lukas RV, Mehta MP, Lesniak MS.

Neurooncol Pract. 2015 Jun;2(2):57-61. Epub 2015 Mar 24. Review.

7.

Natural killer group 2D receptor and its ligands in cancer immune escape.

Duan S, Guo W, Xu Z, He Y, Liang C, Mo Y, Wang Y, Xiong F, Guo C, Li Y, Li X, Li G, Zeng Z, Xiong W, Wang F.

Mol Cancer. 2019 Feb 27;18(1):29. doi: 10.1186/s12943-019-0956-8. Review.

8.

[NEURO-ONCOLOGY A NEW FIELD IN DAVIDOFF CANCER CENTER AT RABIN MEDICAL CENTER].

Yust-Katz S, Limon D, Abu-Shkara R, Siegal T.

Harefuah. 2017 Aug;156(8):512-516. Review. Hebrew.

PMID:
28853528
9.

How many patients require brain mapping in an adult neuro-oncology service?

Giamouriadis A, Lavrador JP, Bhangoo R, Ashkan K, Vergani F.

Neurosurg Rev. 2019 May 19. doi: 10.1007/s10143-019-01112-5. [Epub ahead of print]

PMID:
31104183
10.

Acquired Natural Killer Cell Dysfunction in the Tumor Microenvironment of Classic Hodgkin Lymphoma.

Chiu J, Ernst DM, Keating A.

Front Immunol. 2018 Feb 14;9:267. doi: 10.3389/fimmu.2018.00267. eCollection 2018. Review.

11.

Molecular neuro-oncology: a forward-looking perspective.

Wick W, O'Neill T.

CNS Oncol. 2013 Nov;2(6):491-3. doi: 10.2217/cns.13.47.

12.

The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria.

Nayak L, DeAngelis LM, Brandes AA, Peereboom DM, Galanis E, Lin NU, Soffietti R, Macdonald DR, Chamberlain M, Perry J, Jaeckle K, Mehta M, Stupp R, Muzikansky A, Pentsova E, Cloughesy T, Iwamoto FM, Tonn JC, Vogelbaum MA, Wen PY, van den Bent MJ, Reardon DA.

Neuro Oncol. 2017 May 1;19(5):625-635. doi: 10.1093/neuonc/nox029. Review.

13.

Negative regulation of tumor-infiltrating NK cell in clear cell renal cell carcinoma patients through the exosomal pathway.

Xia Y, Zhang Q, Zhen Q, Zhao Y, Liu N, Li T, Hao Y, Zhang Y, Luo C, Wu X.

Oncotarget. 2017 Jun 6;8(23):37783-37795. doi: 10.18632/oncotarget.16354.

14.

Re-defining response and treatment effects for neuro-oncology immunotherapy clinical trials.

Reardon DA, Okada H.

J Neurooncol. 2015 Jul;123(3):339-46. doi: 10.1007/s11060-015-1748-7. Epub 2015 Feb 24.

15.

Response Assessment in Neuro-Oncology Clinical Trials.

Wen PY, Chang SM, Van den Bent MJ, Vogelbaum MA, Macdonald DR, Lee EQ.

J Clin Oncol. 2017 Jul 20;35(21):2439-2449. doi: 10.1200/JCO.2017.72.7511. Epub 2017 Jun 22. Review.

16.

Mining-Guided Machine Learning Analyses Revealed the Latest Trends in Neuro-Oncology.

Hana T, Tanaka S, Nejo T, Takahashi S, Kitagawa Y, Koike T, Nomura M, Takayanagi S, Saito N.

Cancers (Basel). 2019 Feb 3;11(2). pii: E178. doi: 10.3390/cancers11020178.

17.

Natural killer-like signature observed post therapy in locally advanced rectal cancer is a determinant of pathological response and improved survival.

Alderdice M, Dunne PD, Cole AJ, O'Reilly PG, McArt DG, Bingham V, Fuchs MA, McQuaid S, Loughrey MB, Murray GI, Samuel LM, Lawler M, Wilson RH, Salto-Tellez M, Coyle VM.

Mod Pathol. 2017 Sep;30(9):1287-1298. doi: 10.1038/modpathol.2017.47. Epub 2017 Jun 16.

18.

A team effort: natural killer cells on the first leg of the tumor immunity relay race.

Fessenden TB, Duong E, Spranger S.

J Immunother Cancer. 2018 Jul 9;6(1):67. doi: 10.1186/s40425-018-0380-4.

19.

Development of the Pediatric Neuro-Oncology Rating of Treatment Intensity (PNORTI).

Hocking MC, Hobbie W, Fisher MJ.

J Neurooncol. 2018 Jan;136(1):73-78. doi: 10.1007/s11060-017-2618-2. Epub 2017 Sep 8.

20.

Supplemental Content

Support Center